Experimental mesothelioma vaccine posts promising results

7 May 2018 by under Research/Treatment

syringe vaccine 100x100 Experimental mesothelioma vaccine posts promising resultsBiotech company reported positive results from a limited, Phase I/II clinical study involving its oncolytic virus platform ONCOS-102 and standard-of-care chemotherapy (pemetrexed/cisplatin) in patients with unresectable malignant pleural mesothelioma. After six months, tumor sizes were successfully reduced in three out of six patients treated with the experimental therapy. One patient had a partial response, and the disease was stable in the remaining two patients.

ONCOS-102 works by injecting an oncolytic virus directly into the tumor, which causes the tumor cells to break open and release antigens. The patient’s immune system learns to recognize these antigens and attack other tumor cells.

“Mesothelioma is a challenging disease to treat, with few patients surviving beyond 12 months from diagnosis,” said Dr. Louis Paz-Ares, Chair of the Medical Oncology Department at the University Hospital 12 de Octubre, Madrid, and Principal Investigator of the trial. “The three clinical responses observed in the safety lead-in cohort of the ONCOS-102 trial are encouraging.”

The cancer vaccine was only tested in six patients, which is too small a group to draw conclusions. Targvax plans to see how the treatment works in a larger cohort of 30 patients.

Pleural mesothelioma is the most common form of mesothelioma, a rare but deadly type of cancer. It affects the pleura, the lining that covers the lungs and chest. Pleural mesothelioma is caused by exposure to , a fibrous mineral that occurs naturally in rock and soil. It has been widely used to make a variety of products from building materials to fire-resistant fabrics, and also has been found in talcum powders.

Source: Precision Vaccinations

Comments are closed.